Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Geron expects topline results from IMerge Phase 3 trial in 2H22 » 08:33
07/01/20
07/01
08:33
07/01/20
08:33
GERN

Geron

$2.17 /

+0.07 (+3.34%)

The IMerge Phase 3…

The IMerge Phase 3 clinical trial is a double-blind, randomized, placebo-controlled clinical trial with registration intent. The trial is designed to enroll approximately 170 patients with lower risk transfusion dependent MDS who are relapsed or refractory to an ESA, have not received prior treatment with either a hypomethylating agent or lenalidomide and who are non-del. Geron expects to complete patient enrollment by the end of the first quarter of 2021 and top-line results to be available in the second half of 2022.

ShowHide Related Items >><<
GERN Geron
$2.17 /

+0.07 (+3.34%)

GERN Geron
$2.17 /

+0.07 (+3.34%)

11/19/19 B. Riley FBR
B. Riley FBR resumes Geron with Buy rating, $4 price target
11/19/19 B. Riley FBR
Geron resumed with a Buy at B. Riley FBR
09/03/19 H.C. Wainwright
Geron initiated with a Buy at H.C. Wainwright
08/15/19 Cantor Fitzgerald
Geron initiated with an Overweight at Cantor Fitzgerald
GERN Geron
$2.17 /

+0.07 (+3.34%)

  • 22
    May
GERN Geron
$2.17 /

+0.07 (+3.34%)

Hot Stocks
Geron receives positive COMPvopinion for orphan drug designation for Imetelstat » 08:33
07/01/20
07/01
08:33
07/01/20
08:33
GERN

Geron

$2.17 /

+0.07 (+3.34%)

Geron Corporation…

Geron Corporation announced that the European Medicines Agency Committee for Orphan Medicinal Products issued a positive opinion on the Company's application for orphan drug designation of its first-in-class telomerase inhibitor, imetelstat, as a potential treatment for myelodysplastic syndromes. The Company expects that the European Commission, based on this positive opinion of the COMP, will formally grant the orphan drug designation for the European Union by the end of July. Imetelstat has already been granted orphan drug designation by the United States Food and Drug Administration as a potential treatment for MDS.

ShowHide Related Items >><<
GERN Geron
$2.17 /

+0.07 (+3.34%)

GERN Geron
$2.17 /

+0.07 (+3.34%)

11/19/19 B. Riley FBR
B. Riley FBR resumes Geron with Buy rating, $4 price target
11/19/19 B. Riley FBR
Geron resumed with a Buy at B. Riley FBR
09/03/19 H.C. Wainwright
Geron initiated with a Buy at H.C. Wainwright
08/15/19 Cantor Fitzgerald
Geron initiated with an Overweight at Cantor Fitzgerald
GERN Geron
$2.17 /

+0.07 (+3.34%)

  • 22
    May
GERN Geron
$2.17 /

+0.07 (+3.34%)

Over a week ago
Hot Stocks
Geron reports four imetelstat data presentations at EHA Congress » 08:45
06/12/20
06/12
08:45
06/12/20
08:45
GERN

Geron

$1.66 /

-0.14 (-7.80%)

New Analyses of Data from…

New Analyses of Data from IMbark Phase 2 Clinical Trial in Intermediate-2 or High-risk Myelofibrosis: IMbark was designed as a Phase 2 clinical trial to evaluate two dosing regimens of imetelstatin patients with Intermediate-2 or High-risk myelofibrosis who have relapsed after or are refractory to prior treatment with a janus kinase inhibitor. The co-primary efficacy endpoints for IMbark were spleen response rate, defined as the proportion of patients who achieve a reduction of at least 35% in spleen volume as assessed by imaging, and symptom response rate, defined as the proportion of patients who achieve a reduction of at least 50% in Total Symptom Score, at 24 weeks. Key secondary endpoints were overall survival and safety. Title: Telomerase Activity, Telomere Length and hTERT Expression Correlate with Clinical Outcomes in Higher-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor Treated with Imetelstat. The conclusions of the poster are as follows: Imetelstat achieved dose- and exposure-dependent reduction of telomerase activity and human reverse transcriptase expression level, demonstrating on-target mechanism of action. Achieving optimal pharmacodynamic effect in patients treated with imetelstat is correlated with longer OS, as well spleen and symptom response. Significant dose-dependent reduction in VAF of JAK2, CALR and MPL mutations were observed, indicating that imetelstat has disease-modifying activity by targeting the underlying MF malignant clones. Treatment with 9.4mg/kg of imetelstat improved clinical outcomes in patients with short telomeres or high hTERT expression level at baseline. The results are consistent with telomere biology in cancer cells and provide evidence for on-target mechanism of action of imetelstat through telomerase inhibition. This is the first clinical report to systematically evaluate the mechanism of action based PD effect of imetelstat, and its relationship to exposure and clinical benefits. Title: Imetelstat Treatment Results in Clinical Benefits, Including Improved Overall Survival, in Patients with Higher-Risk Triple Negative Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitors: The overall conclusion of the poster is that triple negative patients who are relapsed/refractory to JAKi and treated with 9.4 mg/kg of imetelstat had better clinical outcomes and prolonged overall survival compared to non-TN patients, suggesting that imetelstat may improve the poor outcomes expected for TN patients. Additional highlights from the poster include: With 9.4 mg/kg of imetelstat treatment, clinical response rates were higher in TN vs non-TN pts: spleen response rate was 18.8% in TN vs 7.3% in non-TN; and symptom response was 50.0% in TN vs 24.4% in non-TN patients. Imetelstat treatment at 9.4 mg/kg resulted in significantly longer median OS of 35.9 months for TN patients compared to 24.6 months for non-TN patients. A majority of the TN patients enrolled on the study had grade three fibrosis. Higher rate of bone marrow fibrosis improvement was noted in the TN vs non-TN patients. TN patients enrolled on the study had short telomere length and high hTERT expression level at baseline, representing a suitable target population for imetelstat, a first-in-class telomerase inhibitor. Gitle: Favorable Overall Survival with Imetelstat Treatment Correlates with Other Clinical Benefits in Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor: The poster reports new analyses of data from all 107 patients in both arms of the IMbark Phase 2 clinical trial with a data cut-off date of February 19, 2020 and a median follow-up of 41.7 months. As of the data cut-off date, median OS was 28.1 months in the 9.4 mg/kg arm and 19.9 months in the 4.7 mg/kg arm. The overall conclusion of the poster was that imetelstat showed dose-related improvement in OS in patients who are R/R to JAKi. The survival benefit observed with imetelstat was supported by the trend of correlation with other clinical benefits. Additional highlights from the poster include: Among 57 patients across both treatment arms that had matching bone marrow samples, 20 patients had greater than or equal to1 degree of bone marrow fibrosis improvement while on study and had a significantly longer OS than those who had worsening bone marrow fibrosis. A similar trend was seen in 29 patients with stable vs. worsening fibrosis. Patients who achieved symptom and spleen response at week 24 showed a trend of longer OS compared to patients who did not achieve response. Transfusion dependency, response to last JAKi, higher baseline neutrophils, lower baseline hemoglobin and platelet values correlated with increased risk of death. The planned Phase 3 clinical trial in refractory MF is designed to be an open label 2:1 randomized, controlled trial with registration intent to evaluate imetelstat in approximately 320 patients with Intermediate-2 or High-risk MF. Patients eligible for the trial will be required to be refractory to a JAK inhibitor, an inclusion criterion that is planned to be defined as having an inadequate spleen response or symptom response after treatment with a JAK inhibitor for at least six months, including an optimal dose of a JAK inhibitor for at least two months. The control arm is planned to be best available therapy , excluding JAK inhibitors. The primary efficacy endpoint for the trial is planned to be overall survival. Planned key secondary endpoints include symptom response, spleen response, progression free survival, complete response, partial response, clinical improvement, duration of response, safety, pharmacokinetics, and patient reported outcomes. Under current assumptions, the Company expects to complete patient enrollment in the second half of 2022, to conduct an interim analysis in the first half of 2023 and to conduct a final analysis in the first half of 2024. The final analysis for OS is planned to be conducted after more than 50% of the patients planned to be enrolled in the trial have died. An interim analysis of OS is planned to be conducted after approximately 70% of the total projected number of events for the final analysis have occurred. Both the planned interim and final analyses are event driven and could occur on different timelines than currently expected. On June 17, 2020, Geron will be hosting a webcasted event with authors from each respective data presentation from the EHA Annual Congress who will reprise the presentations from EHA. A live, listen-only webcast will be available on the Company's website at www.geron.com/investors/events. If you are unable to listen to the live call, an archived webcast will be available on the Company's website for 30 days.

ShowHide Related Items >><<
GERN Geron
$1.66 /

-0.14 (-7.80%)

GERN Geron
$1.66 /

-0.14 (-7.80%)

11/19/19 B. Riley FBR
B. Riley FBR resumes Geron with Buy rating, $4 price target
11/19/19 B. Riley FBR
Geron resumed with a Buy at B. Riley FBR
09/03/19 H.C. Wainwright
Geron initiated with a Buy at H.C. Wainwright
08/15/19 Cantor Fitzgerald
Geron initiated with an Overweight at Cantor Fitzgerald
GERN Geron
$1.66 /

-0.14 (-7.80%)

GERN Geron
$1.66 /

-0.14 (-7.80%)

Hot Stocks
Geron reports four imetelstat data presentations at EHA Congress » 08:45
06/12/20
06/12
08:45
06/12/20
08:45
GERN

Geron

$1.66 /

-0.14 (-7.80%)

Geron Corporation…

Geron Corporation announced that an oral presentation and three poster presentations of new clinical data and analyses related to imetelstat, the Company's first-in-class telomerase inhibitor, are now available on Geron's website as well as to participants of the Virtual Edition of the 25th Annual EHA Annual Congress. Updated Efficacy and Safety Data from IMerge Phase 2 Clinical Trial in Lower Risk Myelodysplastic Syndromes. Title: Treatment with Imetelstat Provides Durable Transfusion Independence in Heavily Transfused Non-del Lower Risk MDS relapsed/Refractory to Erythropoiesis Stimulating Agents. The oral presentation reports long-term efficacy and safety data from 38 patients in the IMerge Phase 2 clinical trial, based on a February 4, 2020 cut-off date and a median follow-up of 24 months. IMerge is a two-part Phase 2/3 clinical trial evaluating imetelstat in transfusion dependent patients with Low or Intermediate-1 risk myelodysplastic syndromes, who are relapsed after or refractory to prior treatment with ESAs. The first part of IMerge was designed as a Phase 2, open label, single arm study to assess the efficacy and safety of imetelstat. The primary efficacy endpoint is 8-week TI rate, which is defined as the proportion of patients achieving red blood cell transfusion independence during any consecutive eight weeks since entry into the trial. Secondary endpoints include rate of hematologic improvement-erythroid and duration of TI. Several patients remain on treatment in the IMerge Phase 2 clinical trial. The conclusions of the oral presentation are as follows: Meaningful and durable transfusion independence: High rates of TI and HI-E: 42% 8-week TI rate and 68% HI-E rate; Durable TI and HI-E: Median duration of TI is 20 months and median duration of HI-E is 21 months; TI across multiple patient subtypes: ringed sideroblast positive and RS-, high and very high transfusion burden. Potential disease-modifying activity: 29% of patients transfusion free for more than 1 year; 75% of 8-week TI responders had a hemoglobin rise of greater than 3g/dL from pretreatment level; Reduction in variant allele frequency of SF3B1 mutation correlated with shorter time to TI and duration of TI. No new safety signal identified: Reversible cytopenias, without significant clinical consequences were most frequent adverse events. Ongoing IMerge Phase 3 Clinical Trial: The IMerge Phase 3 clinical trial is a double-blind, randomized, placebo-controlled clinical trial with registration intent. The trial is designed to enroll approximately 170 patients with lower risk transfusion dependent MDS who are relapsed or refractory to an ESA, have not received prior treatment with either a hypomethylating agent or lenalidomide and who are non-del. The trial was opened for screening and enrollment in August 2019. As of the end of April 2020, approximately 68% of planned clinical sites for the IMerge Phase 3 trial were open for enrollment. Geron expects to complete patient enrollment by the end of the first quarter of 2021. Under current assumptions, the Company expects top-line results to be available in the second half of 2022.

ShowHide Related Items >><<
GERN Geron
$1.66 /

-0.14 (-7.80%)

GERN Geron
$1.66 /

-0.14 (-7.80%)

11/19/19 B. Riley FBR
B. Riley FBR resumes Geron with Buy rating, $4 price target
11/19/19 B. Riley FBR
Geron resumed with a Buy at B. Riley FBR
09/03/19 H.C. Wainwright
Geron initiated with a Buy at H.C. Wainwright
08/15/19 Cantor Fitzgerald
Geron initiated with an Overweight at Cantor Fitzgerald
GERN Geron
$1.66 /

-0.14 (-7.80%)

GERN Geron
$1.66 /

-0.14 (-7.80%)

Over a month ago
Hot Stocks
Geron sees FY20 operating expense burn to range from $70M-75M » 16:09
05/28/20
05/28
16:09
05/28/20
16:09
GERN

Geron

$1.60 /

-0.045 (-2.74%)

The Company expects its…

The Company expects its 2020 operating expense burn to range from $70 to $75 million. This guidance reflects cash conservation measures implemented in April due to the COVID-19 pandemic, such as suspending travel and postponing a planned imetelstat proof of concept study. It also reflects new costs for startup activities associated with the planned Phase 3 clinical trial in refractory MF and additional costs for the expansion of clinical sites for the IMerge Phase 3 clinical trial.

ShowHide Related Items >><<
GERN Geron
$1.60 /

-0.045 (-2.74%)

GERN Geron
$1.60 /

-0.045 (-2.74%)

11/19/19 B. Riley FBR
B. Riley FBR resumes Geron with Buy rating, $4 price target
11/19/19 B. Riley FBR
Geron resumed with a Buy at B. Riley FBR
09/03/19 H.C. Wainwright
Geron initiated with a Buy at H.C. Wainwright
08/15/19 Cantor Fitzgerald
Geron initiated with an Overweight at Cantor Fitzgerald
GERN Geron
$1.60 /

-0.045 (-2.74%)

GERN Geron
$1.60 /

-0.045 (-2.74%)

Earnings
Geron reports Q EPS (8c), consensus (12c) » 16:08
05/28/20
05/28
16:08
05/28/20
16:08
GERN

Geron

$1.61 /

-0.03 (-1.83%)

Reports Q1 revenue $52K,…

Reports Q1 revenue $52K, consensus $50K. As of March 31, 2020, Geron had approximately $133 million in cash, cash equivalents, and current and non-current marketable securities. Based on current planning assumptions, the Company estimates these financial resources, combined with the estimated net proceeds of approximately $140 million from the recently closed public offering of securities, provide sufficient funds for the Company's operations into the second half of 2022 when top-line results for the IMerge Phase 3 clinical trial in lower risk myelodysplastic syndromes are expected, as well completion of patient enrollment for the planned Phase 3 clinical trial in refractory myelofibrosis.

ShowHide Related Items >><<
GERN Geron
$1.61 /

-0.03 (-1.83%)

GERN Geron
$1.61 /

-0.03 (-1.83%)

11/19/19 B. Riley FBR
B. Riley FBR resumes Geron with Buy rating, $4 price target
11/19/19 B. Riley FBR
Geron resumed with a Buy at B. Riley FBR
09/03/19 H.C. Wainwright
Geron initiated with a Buy at H.C. Wainwright
08/15/19 Cantor Fitzgerald
Geron initiated with an Overweight at Cantor Fitzgerald
GERN Geron
$1.61 /

-0.03 (-1.83%)

GERN Geron
$1.61 /

-0.03 (-1.83%)

Syndicate
Geron 107.1M share Spot Secondary priced at $1.30 » 07:20
05/22/20
05/22
07:20
05/22/20
07:20
GERN

Geron

$1.95 /

+0.06 (+3.17%)

Stifel and MTS Health…

Stifel and MTS Health Partners acted as joint book running managers for the offering.

ShowHide Related Items >><<
GERN Geron
$1.95 /

+0.06 (+3.17%)

GERN Geron
$1.95 /

+0.06 (+3.17%)

11/19/19 B. Riley FBR
B. Riley FBR resumes Geron with Buy rating, $4 price target
11/19/19 B. Riley FBR
Geron resumed with a Buy at B. Riley FBR
09/03/19 H.C. Wainwright
Geron initiated with a Buy at H.C. Wainwright
08/15/19 Cantor Fitzgerald
Geron initiated with an Overweight at Cantor Fitzgerald
GERN Geron
$1.95 /

+0.06 (+3.17%)

  • 22
    May
GERN Geron
$1.95 /

+0.06 (+3.17%)

On The Fly
Fly Intel: After-Hours Movers » 19:01
05/21/20
05/21
19:01
05/21/20
19:01
PANW

Palo Alto Networks

$229.36 /

-4.89 (-2.09%)

, RAMP

LiveRamp

$38.70 /

-0.16 (-0.41%)

, CRMT

America's Car-Mart

$73.77 /

+2.825 (+3.98%)

, ELF

e.l.f. Beauty

$14.56 /

+0.34 (+2.39%)

, A

Agilent

$80.84 /

-0.83 (-1.02%)

, SPLK

Splunk

$163.27 /

+0.11 (+0.07%)

, DECK

Deckers Brands

$167.93 /

+5.83 (+3.60%)

, PRSP

Perspecta

$22.93 /

-0.4 (-1.71%)

, PLUS

ePlus

$76.14 /

+4.14 (+5.75%)

, NAVB

Navidea

$1.32 /

+0.06 (+4.76%)

, USFD

US Foods

$18.56 /

-0.24 (-1.28%)

, NYMT

New York Mortgage

$2.04 /

+0.105 (+5.43%)

, AGYS

Agilysys

$20.11 /

+0.79 (+4.09%)

, HPE

HP Enterprise

$10.35 /

+0.07 (+0.68%)

, LGF.A

Lionsgate

$8.61 /

+0.13 (+1.53%)

, ROST

Ross Stores

$97.01 /

+6.1 (+6.71%)

, INTU

Intuit

$290.30 /

-0.4 (-0.14%)

, CHUY

Chuy's

$16.13 /

+0.09 (+0.56%)

, NVDA

Nvidia

$351.01 /

-7.78 (-2.17%)

, SNDX

Syndax

$20.51 /

+0.34 (+1.69%)

, GERN

Geron

$1.95 /

+0.06 (+3.17%)

, CFRX

ContraFect

$5.38 /

-0.22 (-3.93%)

, DSS

Document Security

$8.50 /

+0.22 (+2.66%)

, H

Hyatt

$53.45 /

-0.49 (-0.91%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
USFD US Foods
$18.56 /

-0.24 (-1.28%)

SPLK Splunk
$163.27 /

+0.11 (+0.07%)

SNDX Syndax
$20.51 /

+0.34 (+1.69%)

ROST Ross Stores
$97.01 /

+6.1 (+6.71%)

RAMP LiveRamp
$38.70 /

-0.16 (-0.41%)

PRSP Perspecta
$22.93 /

-0.4 (-1.71%)

PLUS ePlus
$76.14 /

+4.14 (+5.75%)

PANW Palo Alto Networks
$229.36 /

-4.89 (-2.09%)

NYMT New York Mortgage
$2.04 /

+0.105 (+5.43%)

NVDA Nvidia
$351.01 /

-7.78 (-2.17%)

NAVB Navidea
$1.32 /

+0.06 (+4.76%)

LGF.A Lionsgate
$8.61 /

+0.13 (+1.53%)

INTU Intuit
$290.30 /

-0.4 (-0.14%)

HPE HP Enterprise
$10.35 /

+0.07 (+0.68%)

H Hyatt
$53.45 /

-0.49 (-0.91%)

GERN Geron
$1.95 /

+0.06 (+3.17%)

ELF e.l.f. Beauty
$14.56 /

+0.34 (+2.39%)

DSS Document Security
$8.50 /

+0.22 (+2.66%)

DECK Deckers Brands
$167.93 /

+5.83 (+3.60%)

CRMT America's Car-Mart
$73.77 /

+2.825 (+3.98%)

CHUY Chuy's
$16.13 /

+0.09 (+0.56%)

CFRX ContraFect
$5.38 /

-0.22 (-3.93%)

AGYS Agilysys
$20.11 /

+0.79 (+4.09%)

A Agilent
$80.84 /

-0.83 (-1.02%)

PANW Palo Alto Networks
$229.36 /

-4.89 (-2.09%)

05/20/20 Wells Fargo
Palo Alto Networks price target raised to $250 from $225 at Wells Fargo
05/20/20 Monness Crespi
Palo Alto Networks price target raised to $255 from $210 at Monness Crespi
05/19/20
Dougherty sees Palo Alto set up for rebound, upgrades to Buy
05/19/20
Palo Alto Networks upgraded to Buy from Neutral at Dougherty
RAMP LiveRamp
$38.70 /

-0.16 (-0.41%)

04/27/20 Needham
LiveRamp price target lowered to $57 from $70 at Needham
04/21/20 Berenberg
LiveRamp initiated with a Buy at Berenberg
03/13/20 Stephens
LiveRamp weakness creates 'real opportunity,' says Stephens
01/26/20 First Analysis
First Analysis sees continued top-line momentum in 2020 for LiveRamp
CRMT America's Car-Mart
$73.77 /

+2.825 (+3.98%)

03/27/20 Stephens
America's Car-Mart upgraded to Overweight from Equal Weight at Stephens
02/13/20 Janney Montgomery Scott
America's Car-Mart downgraded to Neutral from Buy at Janney Montgomery Scott
ELF e.l.f. Beauty
$14.56 /

+0.34 (+2.39%)

04/08/20 Piper Sandler
Piper lays out winners and losers in survey of 5,200 teens
03/18/20 DA Davidson
e.l.f. Beauty price target lowered to $12 from $24.50 at DA Davidson
02/06/20 Piper Sandler
e.l.f. Beauty price target raised to $23 from $19 at Piper Sandler
02/04/20
Fly Intel: Top five analyst upgrades
A Agilent
$80.84 /

-0.83 (-1.02%)

03/30/20 Wells Fargo
Agilent price target lowered to $82 from $100 at Wells Fargo
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
02/19/20 Piper Sandler
Agilent price target raised to $96 from $86 at Piper Sandler
SPLK Splunk
$163.27 /

+0.11 (+0.07%)

05/14/20 Cleveland Research
Splunk estimates at risk amid enterprise weakness, says Cleveland Research
04/27/20 Needham
Splunk price target lowered to $168 from $181 at Needham
04/24/20 Cowen
Splunk downgraded to Market Perform at Cowen
04/24/20 Cowen
Splunk downgraded to Market Perform from Outperform at Cowen
DECK Deckers Brands
$167.93 /

+5.83 (+3.60%)

05/18/20 Wedbush
Deckers Brands price target raised to $155 from $145 at Wedbush
05/15/20 Pivotal Research
Deckers Brands price target lowered to $165 from $217 at Pivotal Research
05/14/20 Wells Fargo
Wells Fargo downgrades Steven Madden to Underweight on brand weakness
04/28/20 BTIG
Deckers Brands initiated with a Buy at BTIG
PRSP Perspecta
$22.93 /

-0.4 (-1.71%)

04/02/20 Wells Fargo
Perspecta price target lowered to $18.50 from $26 at Wells Fargo
03/30/20 William Blair
Perspecta initiated with a Market Perform at William Blair
03/25/20 Wells Fargo
Good news for government contractors in COVID -19 bill, says Wells Fargo
02/25/20 Morgan Stanley
Morgan Stanley upgrades Perspecta to Equal Weight on overhang removal
PLUS ePlus
$76.14 /

+4.14 (+5.75%)

02/11/20 Berenberg
ePlus upgraded to Buy from Hold at Berenberg
02/06/20 Sidoti
ePlus upgraded to Buy after earnings at Sidoti
02/06/20 Sidoti
ePlus upgraded to Buy from Neutral at Sidoti
11/14/19 Sidoti
ePlus downgraded to Neutral from Buy at Sidoti
NAVB Navidea
$1.32 /

+0.06 (+4.76%)

11/22/19 H.C. Wainwright
Navidea initiated with a Buy at H.C. Wainwright
07/11/19
Fly Intel: Top five analyst initiations
07/11/19 Maxim
Navidea initiated with a Buy at Maxim
07/11/19 Maxim
Navidea initiated with a Buy at Maxim
USFD US Foods
$18.56 /

-0.24 (-1.28%)

05/18/20 Guggenheim
US Foods price target lowered to $30 from $50 at Guggenheim
04/27/20 Credit Suisse
US Foods price target lowered to $27 from $47 at Credit Suisse
04/23/20 BMO Capital
US Foods downgraded to Market Perform from Outperform at BMO Capital
04/06/20 JPMorgan
US Foods price target lowered to $24 from $45 at JPMorgan
NYMT New York Mortgage
$2.04 /

+0.105 (+5.43%)

04/24/20 Credit Suisse
New York Mortgage upgraded to Neutral from Underperform at Credit Suisse
04/24/20 Credit Suisse
New York Mortgage upgraded to Neutral from Underperform at Credit Suisse
03/25/20 Maxim
AGNC Investment, New York Mortgage Trust cut to Hold at Maxim
03/25/20 Maxim
New York Mortgage downgraded to Hold from Buy at Maxim
AGYS Agilysys
$20.11 /

+0.79 (+4.09%)

04/16/20 BTIG
Agilysys initiated with a Neutral at BTIG
03/16/20 Craig-Hallum
Agilysys price target lowered to $27 from $40 at Craig-Hallum
01/29/20 Craig-Hallum
Agilysys price target raised to $40 from $32 at Craig-Hallum
12/03/19 Craig-Hallum
Agilysys initiated with a Buy at Craig-Hallum
HPE HP Enterprise
$10.35 /

+0.07 (+0.68%)

05/19/20 Barclays
Barclays lowers estimates in IT hardware after April survey
04/27/20 Loop Capital
Xerox, Park City, NetApp, HP Enterprise cut to Hold from Buy at Loop Capital
04/27/20 Loop Capital
HP Enterprise downgraded to Hold from Buy at Loop Capital
04/22/20
Fly Intel: Top five analyst initiations
LGF.A Lionsgate
$8.61 /

+0.13 (+1.53%)

04/27/20 RBC Capital
Lionsgate initiated with a Sector Perform at RBC Capital
04/22/20 Deutsche Bank
Lionsgate price target lowered to $10 from $22 at Deutsche Bank
04/21/20 JPMorgan
Lionsgate price target lowered to $11 from $14 at JPMorgan
03/23/20
Lionsgate participates in a conference call with SunTrust
ROST Ross Stores
$97.01 /

+6.1 (+6.71%)

05/19/20 Jefferies
TJX to benefit from 'biggest liquidation sale in history,' says Jefferies
05/11/20 Nomura Instinet
Ross Stores price target raised to $100 from $80 at Nomura Instinet
04/28/20 DA Davidson
Ross Stores upgraded to Buy from Neutral at DA Davidson
04/28/20 DA Davidson
Ross Stores upgraded to Buy from Neutral at DA Davidson
INTU Intuit
$290.30 /

-0.4 (-0.14%)

05/19/20 KeyBanc
Intuit price target raised to $315 from $285 at KeyBanc
05/05/20 KeyBanc
Intuit price target raised to $285 from $275 at KeyBanc
04/17/20 RBC Capital
Intuit lowered to $280 from $345 at RBC Capital
04/13/20 Jefferies
Jefferies continues to like Intuit after approval for small business lending
CHUY Chuy's
$16.13 /

+0.09 (+0.56%)

04/23/20 BMO Capital
Chuy's upgraded to Market Perform from Underperform at BMO Capital
04/20/20 Raymond James
Chuy's price target raised to $17 from $14 at Raymond James
04/08/20 Wedbush
Chuy's price target lowered to $17 from $26 at Wedbush
04/02/20 Raymond James
Chuy's upgraded to Outperform from Market Perform at Raymond James
NVDA Nvidia
$351.01 /

-7.78 (-2.17%)

05/21/20 Credit Suisse
Nvidia reinstated with an Outperform at Credit Suisse
05/19/20 RBC Capital
Nvidia price target raised to $385 from $350 at RBC Capital
05/19/20 Susquehanna
Nvidia price target raised to $410 from $355 at Susquehanna
05/18/20
Fly Intel: Top five analyst upgrades
SNDX Syndax
$20.51 /

+0.34 (+1.69%)

05/18/20 Citi
Syndax downgraded to Neutral from Buy at Citi
05/11/20 H.C. Wainwright
Syndax price target raised to $25 from $19 at H.C. Wainwright
05/08/20 Nomura Instinet
Syndax price target raised to $31 from $16 at Nomura Instinet
05/04/20 Baird
Syndax risk/reward solid following positive clinical data, says Baird
GERN Geron
$1.95 /

+0.06 (+3.17%)

11/19/19 B. Riley FBR
B. Riley FBR resumes Geron with Buy rating, $4 price target
11/19/19 B. Riley FBR
Geron resumed with a Buy at B. Riley FBR
09/03/19 H.C. Wainwright
Geron initiated with a Buy at H.C. Wainwright
08/15/19 Cantor Fitzgerald
Geron initiated with an Overweight at Cantor Fitzgerald
CFRX ContraFect
$5.38 /

-0.22 (-3.93%)

10/02/19 Piper Sandler
Piper says design differentiates ContraFect trial from other antibiotic studies
06/11/19 Maxim
ContraFect initiated with a Buy at Maxim
DSS Document Security
$8.50 /

+0.22 (+2.66%)

10/10/19 Aegis
Document Security initiated with a Buy rating at Aegis
H Hyatt
$53.45 /

-0.49 (-0.91%)

05/08/20
Fly Intel: Top five analyst downgrades
05/08/20 Deutsche Bank
Hyatt price target lowered to $54 from $86 at Deutsche Bank
05/08/20 Macquarie
Hyatt downgraded to Neutral from Outperform at Macquarie
04/22/20 BofA
Choice Hotels upgraded to Neutral from Underperform at Bofa
USFD US Foods
$18.56 /

-0.24 (-1.28%)

SPLK Splunk
$163.27 /

+0.11 (+0.07%)

SNDX Syndax
$20.51 /

+0.34 (+1.69%)

ROST Ross Stores
$97.01 /

+6.1 (+6.71%)

RAMP LiveRamp
$38.70 /

-0.16 (-0.41%)

PRSP Perspecta
$22.93 /

-0.4 (-1.71%)

PLUS ePlus
$76.14 /

+4.14 (+5.75%)

PANW Palo Alto Networks
$229.36 /

-4.89 (-2.09%)

NYMT New York Mortgage
$2.04 /

+0.105 (+5.43%)

NVDA Nvidia
$351.01 /

-7.78 (-2.17%)

LGF.A Lionsgate
$8.61 /

+0.13 (+1.53%)

INTU Intuit
$290.30 /

-0.4 (-0.14%)

HPE HP Enterprise
$10.35 /

+0.07 (+0.68%)

H Hyatt
$53.45 /

-0.49 (-0.91%)

GERN Geron
$1.95 /

+0.06 (+3.17%)

ELF e.l.f. Beauty
$14.56 /

+0.34 (+2.39%)

DSS Document Security
$8.50 /

+0.22 (+2.66%)

DECK Deckers Brands
$167.93 /

+5.83 (+3.60%)

CRMT America's Car-Mart
$73.77 /

+2.825 (+3.98%)

CHUY Chuy's
$16.13 /

+0.09 (+0.56%)

CFRX ContraFect
$5.38 /

-0.22 (-3.93%)

AGYS Agilysys
$20.11 /

+0.79 (+4.09%)

A Agilent
$80.84 /

-0.83 (-1.02%)

  • 22
    May
  • 22
    May
  • 22
    May
ROST Ross Stores
$97.01 /

+6.1 (+6.71%)

PANW Palo Alto Networks
$229.36 /

-4.89 (-2.09%)

NVDA Nvidia
$351.01 /

-7.78 (-2.17%)

LGF.A Lionsgate
$8.61 /

+0.13 (+1.53%)

INTU Intuit
$290.30 /

-0.4 (-0.14%)

HPE HP Enterprise
$10.35 /

+0.07 (+0.68%)

H Hyatt
$53.45 /

-0.49 (-0.91%)

A Agilent
$80.84 /

-0.83 (-1.02%)

USFD US Foods
$18.56 /

-0.24 (-1.28%)

SPLK Splunk
$163.27 /

+0.11 (+0.07%)

SNDX Syndax
$20.51 /

+0.34 (+1.69%)

RAMP LiveRamp
$38.70 /

-0.16 (-0.41%)

PRSP Perspecta
$22.93 /

-0.4 (-1.71%)

PANW Palo Alto Networks
$229.36 /

-4.89 (-2.09%)

NYMT New York Mortgage
$2.04 /

+0.105 (+5.43%)

NVDA Nvidia
$351.01 /

-7.78 (-2.17%)

LGF.A Lionsgate
$8.61 /

+0.13 (+1.53%)

INTU Intuit
$290.30 /

-0.4 (-0.14%)

HPE HP Enterprise
$10.35 /

+0.07 (+0.68%)

H Hyatt
$53.45 /

-0.49 (-0.91%)

ELF e.l.f. Beauty
$14.56 /

+0.34 (+2.39%)

DECK Deckers Brands
$167.93 /

+5.83 (+3.60%)

CHUY Chuy's
$16.13 /

+0.09 (+0.56%)

A Agilent
$80.84 /

-0.83 (-1.02%)

SPLK Splunk
$163.27 /

+0.11 (+0.07%)

ROST Ross Stores
$97.01 /

+6.1 (+6.71%)

PANW Palo Alto Networks
$229.36 /

-4.89 (-2.09%)

NYMT New York Mortgage
$2.04 /

+0.105 (+5.43%)

NVDA Nvidia
$351.01 /

-7.78 (-2.17%)

INTU Intuit
$290.30 /

-0.4 (-0.14%)

HPE HP Enterprise
$10.35 /

+0.07 (+0.68%)

H Hyatt
$53.45 /

-0.49 (-0.91%)

A Agilent
$80.84 /

-0.83 (-1.02%)

Hot Stocks
Geron provides update on ongoing Phase 3 IMerge trial » 16:13
05/21/20
05/21
16:13
05/21/20
16:13
GERN

Geron

$1.96 /

+0.065 (+3.44%)

Geron provided an update…

Geron provided an update on its ongoing IMerge Phase 3 clinical trial in lower risk MDSAs. As of the end of April, approximately 68% of planned clinical sites for the IMerge Phase 3 clinical trial in lower risk MDS were open for enrollment. Due to the effects of the COVID-19 pandemic on site initiations and enrollment, Geron now plans to complete patient enrollment by the end of Q1 of 2021. To facilitate this timing, the company is currently evaluating the feasibility of increasing the number of participating countries by six, and the number of clinical sites by 40. Following 15 months from the last patient being enrolled, a primary analysis of efficacy and safety data from the trial will begin to enable top-line results. Under current assumptions, the company expects top-line results to be available in the second half of 2022. This anticipated timing is subject to potential delays or interruptions associated with the evolving effects of the COVID-19 pandemic, regardless of Geron's evaluation of additional countries and sites. The IMerge Phase 3 clinical trial has been designed with more than 85% power to detect a statistically significant difference in the primary endpoint of 8-week transfusion independence between the imetelstat treatment arm and the placebo arm. Based on discussions with U.S. and European regulatory authorities, Geron believes the IMerge Phase 3 clinical trial, if successful, will support the registration of imetelstat in lower risk MDS.

ShowHide Related Items >><<
GERN Geron
$1.96 /

+0.065 (+3.44%)

GERN Geron
$1.96 /

+0.065 (+3.44%)

11/19/19 B. Riley FBR
B. Riley FBR resumes Geron with Buy rating, $4 price target
11/19/19 B. Riley FBR
Geron resumed with a Buy at B. Riley FBR
09/03/19 H.C. Wainwright
Geron initiated with a Buy at H.C. Wainwright
08/15/19 Cantor Fitzgerald
Geron initiated with an Overweight at Cantor Fitzgerald
GERN Geron
$1.96 /

+0.065 (+3.44%)

Hot Stocks
Geron announces plans for Phase 3 imetelstat trial in MF patients » 16:07
05/21/20
05/21
16:07
05/21/20
16:07
GERN

Geron

$1.96 /

+0.07 (+3.70%)

Geron announced plans for…

Geron announced plans for a Phase 3 clinical trial in MF patients who are refractory to treatment with a janus kinase, or JAK, inhibitor, including trial design and expected timelines for trial start and future data readouts. The planned Phase 3 clinical trial in refractory MF is designed to be an open label 2:1 randomized, controlled trial to evaluate imetelstat in approximately 320 patients with Intermediate-2 or High-risk MF. Patients eligible for the trial will be required to be refractory to a JAK inhibitor, an inclusion criterion that is planned to be defined as having an inadequate spleen response or symptom response after treatment with a JAK inhibitor for at least six months, including an optimal dose of a JAK inhibitor for at least two months. The control arm is planned to be best available therapy, or BAT, excluding JAK inhibitors. The primary efficacy endpoint for the trial is planned to be overall survival, or OS. Planned key secondary endpoints include symptom response, spleen response, progression free survival, complete response, partial response, clinical improvement, duration of response, safety, pharmacokinetics, and patient reported outcomes. Currently, the planned Phase 3 clinical trial in refractory MF has been designed with more than 85% power to detect a 40% reduction in the risk of death for the imetelstat treated patients, for example, 14 months for the BAT arm and 23 months for the imetelstat arm. The final analysis for OS is planned to be conducted after more than 50% of the total enrolled patients have died. An interim analysis of OS, in which the alpha spend is expected to be approximately 0.01, is planned to be conducted after approximately 70% of the total projected number of events, or deaths, for the final analysis have occurred. At the interim analysis, if the pre-specified statistical OS criterion is met, then Geron expects such data may support registration of imetelstat in refractory MF. If the prespecified OS criterion is not met at interim analysis, the trial will continue to the final analysis. Both the planned interim and final analyses are event driven and could occur on different timelines than currently expected. The trial design for the planned Phase 3 clinical trial in refractory MF was discussed with the FDA at a Type C meeting in Q2. The FDA accepted the proposed trial design, including the definition of the refractory MF patient population, the primary efficacy endpoint of OS, secondary endpoints, the use of BAT for the control arm that excludes JAK inhibitors, and the statistical design and methods to be used to analyze data from the trial for the interim and final analyses. Although the FDA urged Geron to consider a third dosing arm to assess a lower dose and/or a more frequent dosing schedule that might identify a less toxic regimen and/or improve spleen response, one of the trial's secondary endpoints, the FDA did not object to Geron's proposed imetelstat dose and schedule of 9.4 mg/kg every three weeks. Geron believes the current design of the planned Phase 3 clinical trial will support, if the trial is successful, the registration of imetelstat in refractory MF. Currently, Geron expects to engage over 150 sites to participate in the global Phase 3 clinical trial in refractory MF across North America, South America, Europe and Asia. Geron plans to open the trial for screening and enrollment in Q1 of 2021. Under current assumptions, Geron expects to complete patient enrollment in the planned Phase 3 clinical trial in refractory MF in the second half of 2022, to conduct an interim analysis in the first half of 2023 and to conduct a final analysis in the first half of 2024. The timing and achievement of enrollment completion and either or both of the planned analyses depend on numerous factors, including obtaining regulatory clearance of the trial protocol, Geron's ability to raise additional capital, and delays or interruptions related to the evolving effects of the COVID-19 pandemic.

ShowHide Related Items >><<
GERN Geron
$1.96 /

+0.07 (+3.70%)

GERN Geron
$1.96 /

+0.07 (+3.70%)

11/19/19 B. Riley FBR
B. Riley FBR resumes Geron with Buy rating, $4 price target
11/19/19 B. Riley FBR
Geron resumed with a Buy at B. Riley FBR
09/03/19 H.C. Wainwright
Geron initiated with a Buy at H.C. Wainwright
08/15/19 Cantor Fitzgerald
Geron initiated with an Overweight at Cantor Fitzgerald
GERN Geron
$1.96 /

+0.07 (+3.70%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.